Cell Therapy News/Articles, page-6307

My apologies if this has been previously included on the MSB forum, but unfortunately there are just too many posts to keep up. For those that haven't seen this article that appeared in the online version of todays "The Australian", it is another example of the beneficial effect our company and it's products can and will have for those that suffer the more extreme effects of contracting Covid-19.
The article is entitled : "Four-year-old COVID-19 patient recovers thanks to Mesoblast drug". Some excerpts from the article are as follows:

"When four-year-old KJ Griffin’s mother rushed him to a hospital in South Carolina, with his body limp, she didn’t think he had COVID-19, let alone that he would eventually be treated with an experimental Australian drug that would save his life."

"KJ had caught the highly infectious virus weeks earlier."

"The coronavirus had left its mark in the form of multisystem inflammatory syndrome in children (MIS-C), a rare and potentially lethal complication from COVID-19.

MIS-C develops two to four weeks after a COVID-19 infection and triggers an immune response that attacks vital organs, including the heart, lungs, kidneys and brain."

"Dr Eckard treated KJ at MUSC’s Shawn Jenkins Hospital in Charleston. When he arrived at the hospital’s emergency department his body was in shock, unable to get enough blood flow to his vital organs."

"Dr Eckard was able to save his life after securing access to Mesoblast’s remestemcel-L, a drug the ASX-listed company is currently trialling in the US to treat severe complications from COVID-19."

"Dr Eckard said “We gave him all of the standard treatments and it didn’t help. That’s why we decided to treat him with the Mesoblast product.”"

" KJ responded almost instantly."

"KJ had two infusions of remestemcel-L, which Dr Eckard said was the standard protocol, and was discharged a week and a half later, making a full recovery."

"Mesoblast has made remestemcel-L available to doctors for treatment of COVID-19-infected children with multisystem inflammatory syndrome under the company’s Expanded Access Program."